Four mexiletine analogues have been tested for their antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig heart tissues and to assess calcium antagonist activity, in comparison with the parent compound mexiletine. All analogues showed from moderate to high antiarrhythmic activity. In particular, three of them (1b,c,e) were more active and potent than the reference drug, while exhibiting only modest or no negative inotropic and chronotropic effects and vasorelaxant activity, thus showing high selectivity of action. All compounds showed no cytotoxicity and 1b,c,d did not impair motor coordination. All in, these new analogues exhibit an interesting cardiovascular profile and deserve further investigation.
One of the major causes of mortality is represented by cardiovascular diseases and about 25% of cardiovascular-related adverse events are caused by arrhythmias. The term arrhythmia defines an abnormality in the sequence and/or shape of electrical impulses during the cardiac cycle. A critical role in the regulation of electrical activity of cardiac cells is played by ion channels such as sodium, calcium and potassium channels. Abnormalities in the expression and/or function of ion channels are responsible of many arrhythmias [1, 2] , thus, they represent one of the targets for antiarrhythmic therapy. Indeed, most of the existing antiarrhythmic agents, such as lidocaine, tocainide, and mexiletine [3, 4] are ion channel blockers. Mexiletine (1a, Fig. 1 ) is an antiarrhythmic drug belonging to class IB. It is a voltage-gated sodium channel blocker whose mechanism of action is related to its preferential binding to the open and/or inactivated states of the channels. The selective action of mexiletine on pathologically hyperactive tissues seems to be related to the use-dependent blockade of sodium channels [5] . Mexiletine undergoes extensive metabolism; eleven phase I metabolites of mexiletine have been identified [6, 7] . Mexiletine is predominantly used in the treatment of ventricular arrhythmias, however, recent studies have demonstrated its therapeutic value for treating many other disorders associated with voltage-gated sodium channel Abbreviations used: CNS, central nervous system; DMEM, Dulbecco's modified eagle's medium; GPILSM, guinea pig ileum longitudinal smooth muscle; HepG2, human hepatocellular liver carcinoma cells; MDCK, Madin-Darby canine kidney; MDCK-MDR1, MDCK overexpressing P-gp; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MW, microwave; P-gp, P-glycoprotein; PSS, physiological salt solution.
dysfunction including chronic painful diabetic neuropathy [8] , neuropathic pain [9] , myotonic syndromes [10] , and Timothy syndrome [11] . Recently, mexiletine has been successfully used in the treatment of sporadic amyotrophic lateral sclerosis [12e14] . Despite all these reported therapeutic values, the use of mexiletine is characterized by several drawbacks including epigastric discomfort, atrioventricular heart block, and CNS disturbances [15] . Hence, it has now been discontinued in many countries including the US and the UK [16] . Consequently, numerous attempts have been made in recent years to develop an alternative to mexiletine, including the design of new analogues that offer the same pharmacological effect but without the unwanted side effects. In the past decade, our own laboratories have been focusing on the development of such analogues through which the structural determinants for blocking voltage-gated sodium channels of skeletal muscles have been established [17e20] . As these identified compounds were more potent channel blockers than the parent compound, they have been proposed as mexiletine alternatives for the treatment of myotonias. We also established that the activity of mexiletine-like sodium channel blockers is strongly linked to the part of the molecule nearby the asymmetric carbon atom. In order to evaluate the potential of these compounds for treating arrhythmias, we selected the most interesting compounds from the previously reported series (1cee, Fig. 1 ) that bear a bulky group at the stereogenic center. These compounds, along with a new additional compound, 1b, bearing a tert-butyl group as substituent were prepared by alternative and efficient synthetic routes. The biological activity of all compounds was assessed with due comparison with mexiletine.
Results and discussion

Chemistry
Mexiletine (1a) and its analogues (1b,c) were prepared in two steps according to the synthetic route depicted in Scheme 1, carried out in both traditional conditions and microwave-assisted synthesis. In the first step, 2,6-dimethylphenol underwent Williamson reaction [21] with the suitable halo ketone (2aec) to obtain aryloxyalkyl ketones (3aec) which were converted into the corresponding amines 1aec by reductive amination under both traditional and microwave conditions [22] . The corresponding hydrochloride salts (1aec·HCl) were obtained by treating 1aec with gaseous HCl. Mexiletine analogues 1d,e were prepared as depicted in Scheme 2. Compounds 5d,e were obtained by protecting the corresponding commercial valinol and phenylalaninol, respectively, with di-tert-butyl dicarbonate [23, 24] . Compounds 5d,e were subjected to Mitsunobu reaction with 2,6-dimethylphenol as previously described [25] . The so obtained aryl alkyl ethers 6d,e were treated with gaseous HCl to give the corresponding amines as hydrochloride salts (1d,e·HCl).
Biological results
Mexiletine and its analogues (1aee) were tested in vitro for their antiarrhythmic activity on guinea pig isolated left atria driven at 1 Hz. Compound 1b,c,e increased the threshold of ac-arrhythmia more than mexiletine did, while 1d showed an anti-arrhythmic activity comparable to that of the parent compound, mexiletine ( Table 1 ). In particular, compound 1c was found to be 27-fold more active than mexiletine. To better define the cardiac profile of mexiletine analogues, their influence on additional cardiac parameters were compared with that elicited by the reference compound, mexiletine ( Table 2 ). All the tested compounds strongly decreased the developed tension on driven left atria with EC 50 values within the range of 0.012 and 0.042 mM. The most potent analogue was 1e showing a negative inotropism 4-fold higher than that of mexiletine (Table 2) , while its antiarrhythmic potency was 2.7-fold higher than that of mexiletine ( Table 1 ). The effect of 1b was comparable to that of mexiletine. It is noteworthy that the introduction of an aromatic moiety, in lieu of the methyl one, on the stereogenic center as in 1c and 1e, strongly increased antiarrhythmic and negative inotropic potency. On the other hand, the introduction of an isopropyl group, as in 1d, while slightly affecting the antiarrhythmic activity, enhanced two times the negative inotropic effect. With regard to the negative chronotropic activity on spontaneously beating right atrium, only compound 1d showed a weak activity, about 900-fold lower than that of mexiletine. Furthermore, 1b,c,e showed negative inotropism on spontaneously beating isolated right atrium, too. It is noteworthy that this effect was not recorded for mexiletine and 1d due to their insignificant inotropism resulting from chronotropic effect. Moreover, all the new mexiletine analogues were tested on K þ -depolarized (80 mM KCl) guinea pig aortic strips to assess their vasorelaxant activity. Data are shown in Table 3 with mexiletine as the reference drug. For all compounds, the intrinsic vasorelaxant activity percentage on aorta was lower than 40% and thus unremarkable. In order to rule out a possible inhibitory effect on nonvascular smooth muscle, such as that displayed by Ca 2þ channel antagonists, further investigation on relaxant activity using K þ -depolarized (80 mM KCl) guinea pig ileum longitudinal smooth muscle (GPILSM) was pursued ( Table 3 ). The observed profile of intrinsic activity and potency for 1b,c,d was, however, substantially similar to that displayed by mexiletine. Only compound 1e showed a relaxant potency slightly higher than that of the parent compound, but in the micromolar range. Over all, all the compounds appears to display a higher intrinsic activity in nonvascular than vascular smooth muscle cells. Since mexiletine clinical use is often associated to CNS toxicity, a preliminary toxicological evaluation of mexiletine analogues was performed by assessing the motor coordination of treated animals using the rotarod test (Table 4 ). All compounds at the dose of 25 mg/kg ip did not a Increase of threshold of ac-arrhythmia: increase in the intensity of 50 Hz alternating current required to produce arrhythmia in guinea pig left atria driven at 1 Hz in the presence of each tested compounds at 10 À4 M. For all data P < 0.05. b Calculated from log concentration-response curves (Probit analysis according to Litchfield and Wilcoxon [35] with n ¼ 6e8). When the maximum effect was <50%, the EC 50 values were not calculated.
c At 10 Decrease in developed tension on isolated guinea-pig left atrium at 10 À5 M, expressed as percentage change from the control (n ¼ 5e6). The left atria were driven at 1 Hz.
The 10 À5 M concentration gave the maximum effect for most compounds. b Calculated from log concentration-response curves (Probit analysis by Litchfield and Wilcoxon [35] with n ¼ 6e7). When the maximum effect was <50%, the EC 50 inotropic, EC 50 chronotropic and IC 50 vasorelaxant values were not calculated.
c Decrease in developed tension on guinea-pig spontaneously beating isolated right atrium at 5 Â 10 À6 M, expressed as percent changes from the control (n ¼ 7e8). The 5 Â 10 À6 M concentration gave the maximum effect for most compounds. d Decrease in atrial rate on guinea-pig spontaneously beating isolated right atria at 10 À5 M, expressed as the percentage change from the control (n ¼ 7e8). The 10 À5 M concentration gave the maximum effect for most compounds. The pretreatment heart rate ranged from 170 to 195 beats/min. e At 5 Â 10
05. An asterisk indicates P < 0.05. provoke any change in normal behavior of mice as demonstrated in rota-rod experiments. At the dose of 50 mg/kg ip, only compound 1e showed a significant impairment of mouse motor coordination, with a slight increase in the number of falls being displayed. Since mexiletine is known to undergo extensive first-pass oxidative metabolism [16, 26, 27] that is linked to the generation of reactive species metabolites and/or cellular oxidative stress, the cytotoxicity of the four analogues was assessed using the MTT cell viability assay [28] . When the human hepatocellular liver carcinoma cells (HepG2) were challenged with the four mexiletine analogues at two concentrations (the first close to their corresponding EC 50 values, and the second 10-fold higher than the former), no cytotoxicity was observed (data not shown). This finding was in agreement with the previous report for mexiletine where cell viability was not affected at similar concentration range [16] . In addition, we tried to verify if these analogues may display differential ability to interact with Pglycoprotein (P-gp), an ATPase protein highly expressed in biological membranes, that generally affects pharmacokinetics, efficacy, safety, and tissue levels of drugs. For this, drug-protein interaction was assessed for each compound by using the Madin-Darby canine kidney (MDCK) cells overexpressing the ATPase protein P-gp (MDCK-MDR1). As shown in Table 5 , only compounds that bear a phenyl ring near the basic center (1c,e) was able to bind P-gp. This data was in good agreement with a recent study on a series of structurally related rigid analogues [29] .
Conclusions
Four mexiletine analogues differing for the substituent on the stereogenic center have been tested for their antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig heart tissues and for their calcium antagonist activity on GPILSM, in comparison with mexiletine. Even if with different degrees of potency, antiarrhythmic activity has been observed in all the studied compounds, conceivably suggesting the hypothesis that the substitution of the methyl group of mexiletine with a bulky one, strengthens the interaction with the biological structures involved in the regulation of heart activity. In particular, compounds 1b,c,e showed high antiarrhythmic activity, exhibiting EC 50 values in the range between 0.43 and 4.36 mM, thus comparing favorably with the reference drug mexiletine (EC 50 ¼ 11.6 mM). These compounds exhibit an interesting cardiovascular profile, being endowed with high antiarrhythmic activity and potency with only modest or no negative inotropic and chronotropic effects and vasorelaxant activity. When administered intraperitoneally (25 mg kg À1 ), all compounds did not impair motor coordination as demonstrated in rota-rod experiments and showed no in vitro cytotoxicity at concentration 10 times higher than the corresponding antiarrhythmic EC 50 values. On the basis that the observed favorable profile should not be affected by interaction with P-gp, compounds 1b and 1d could be considered as the preferred choices. Taken all the data together, this work afforded compounds endowed with better antiarrhythmic activity along with similar or less cardiovascular effects than mexiletine, thus presenting a higher selectivity of action and reduced side effects. In this respect, the t-butyl substituted mexiletine analogue 1b seems to be the most interesting compound. Further investigation would allow more complete knowledge about its pharmacological potential and mechanism of action, which in turn might allow the design and development of even more active and potent antiarrhythmic agents.
Experimental protocols
Chemistry
Chemicals were purchased from Sigma-Aldrich or Lancaster. Yields refer to purified products and were not optimized. The structures of the compounds were confirmed by routine spectrometric and spectroscopic analyses. Only spectra for compounds not previously described are given. The reaction under microwaves irradiation were carried out at constant temperature in a CEM Discover BenchMate microwave reactor, with continuous stirring. The temperature was measured and controlled by a built-in infrared detector. Melting points were determined on a Gallenkamp apparatus in open glass capillary tubes and are uncorrected. Infrared spectra were recorded on a Perkin-Elmer (Norwalk, CT) Spectrum One FT spectrophotometer and band positions are given [30] . TLC analyses were performed on precoated silica gel on aluminum sheets (Kieselgel 60 F 254 , Merck).
1-(2,6-Dimethylphenoxy)propan-2-amine (1a)
The preparation of 1a was performed under both traditional (method A) and microwaves conditions (method B) [31] .
4.1.1.1. Method A. Ammonium acetate (23.8 g, 310 mmol) and sodium cyanoborohydride (1.4 g, 21.7 mmol) were added to a solution of 1-(2,6-dimethylphenoxy)propan-2-one (3a) (5.5 g, 31 mmol) in 40 mL of MeOH. The reaction mixture was stirred for four days at room temperature. 6 M HCl was added dropwise to the mixture reaction to destroy the excess hydride. The organic solvent was removed under vacuum and the residue aqueous phase was made alkaline with NaOH pellets. Then, the aqueous phase was extracted with AcOEt and the combined organic phases were dried (Na 2 SO 4 ). The solvent was evaporated under reduced pressure to give the desired amine (1a) as a yellow oil (4.5 g, 81%). Spectroscopic data were in agreement with the literature [21] .
Method B.
In a microwave tube, ammonium acetate (7.35 g, 95.5 mmol) and sodium cyanoborohydride (0.42 g, 6.7 mmol) were added to a solution of 1-(2,6-dimethylphenoxy)propan-2-one (3a) (1.7 g, 9.55 mmol) in 15 mL of MeOH. The reaction mixture was stirred for 11 min at 110 C in a microwave reactor at 95 W as power max. The processing of reaction mixture was carried out as reported for method A, obtaining 1a in 72% yield. Spectrometric and spectroscopic data were in agreement with the literature [21] .
1-(2,6-Dimethylphenoxy)propan-2-amine hydrochloride (1a·HCl)
1a was treated with gaseous HCl to obtain the corresponding hydrochloride salt (1a·HCl) as a white solid which was recrystallized from EtOH/Et 2 O to afford 2.9 g (40%) of white crystals: mp 215e216 C; 
Pharmacology
4.2.1. Details for functional studies 4.2.1.1. Guinea-pig atrial preparations. Female guinea pigs (300e400 g) were sacrificed by cervical dislocation. After thoracotomy, the heart was immediately removed and washed by perfusion through the aorta with oxygenated Tyrode solution of the following composition (mM): 136.9 NaCl, 5.4 KCl, 2.5 CaCl 2 , 1.0 MgCl 2 , 0.4 NaH 2 PO 4 xH 2 O, 11.9 NaHCO 3 and 5.5 glucose. The physiological salt solution (PSS) was buffered at pH 7.4 by saturation with 95% O 2 e5% CO 2 gas, and the temperature was maintained at 35 C. Isolated guinea pig heart preparations were used, spontaneously beating right atria and left atria driven at 1 Hz. For each preparation, the entire left and right atria were dissected from the ventricles, cleaned of excess tissue, and hung vertically in a 15 mL organ bath containing the PSS continuously bubbled with 95% O 2 e5% CO 2 gas at 35 C, pH 7.4. The contractile activity was recorded isometrically by means of a force transducer (FT 0.3, Grass Instruments Corporation, Quincy, MA, USA) using Power Lab ® software (AD-Instruments Pty Ltd, Castle Hill, Australia). The left atria were stimulated by rectangular pulses of 0.6e0.8 ms duration and about 50% threshold voltage through two platinum contact electrodes in the lower holding clamp (Grass S88 Stimulator). The right atrium was in spontaneous activity. After the tissue was beating for several minutes, a length-tension curve was determined, and the muscle length was maintained which elicited 90% of maximum contractile force observed at the optimal length. A stabilization period of 45e60 min was allowed before the atria were used to test compounds. During the equilibration period, the bathing solution was changed every 15 min and the threshold voltage was ascertained for the left atria. Atrial muscle preparations were used to examine the inotropic and chronotropic activity of the compounds (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, and 100 mM) dissolved in PSS. During the construction of cumulative dose-response curves, the next higher concentration of the compounds was added only after the preparation reached a steady state.
Alternating current induced arrhythmia in
Guinea pig left atrial preparations [32, 33] . Left atria from guinea pigs were fixed to platinum wire electrodes and placed between two parallel platinum field electrodes. The preparations were mounted vertically in a 15 mL organ bath containing a modified Krebs-Henselait solution of the following composition (mM): 118 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 NaH 2 PO 4 xH 2 O, 24.9 NaHCO 3 , and 10.1 glucose. The solution was buffered at pH 7.4 by saturation with 95% O 2 e5% CO 2 gas, and the temperature was maintained at 35 C. The preparations were connected to a force transducer. Isometric force contraction was recorded using Power Lab ® software. Arrhythmias were induced by application of sinusoidal alternating current (50 Hz) of increasing strength to the isolated heart preparations, 2 and 4 mA/ (cm 2 s) to induce arrhythmia corresponding to an increase in field intensity of 0.3 V/(cm s). The current intensity (mA/cm 2 ) at which extra beats occurred was called "threshold of ac-arrhythmia" [34] . The preparations were allowed to stabilize for 60 min. Then concentration-response curves for threshold of ac-arrhythmia were recorded by cumulative application of compounds to the bathing solution every 30 min. and 11 glucose equilibrated with 95% O 2 e5% CO 2 gas at pH 7.4. The vessel was cleaned of extraneous connective tissue. Two helicoidal strips (10 mm Â 1 mm) were cut from each aorta beginning from the end most proximal to the heart. Vascular strips were then tied with surgical thread (6-0) and suspended in a jacketed tissue bath (15 mL) containing aerated PSS at 35 C. Aortic strips were subjected to a resting force of 1 g. Strips were secured at one end to a force displacement transducer (FT 0.3, Grass Instruments Corporation) to monitor changes in isometric contraction and washed every 20 min with fresh PSS for 1 h after the equilibration period; guinea pig aortic strips were contracted by washing in PSS containing 80 mM KCl (equimolar substitution of K þ for Na þ ). After the contraction reached a plateau (about 45 min) the compounds (0.1, 0.5, 1, 5, 10, 50, and 100 mM) were added cumulatively to the bath allowing for any relaxation to obtain an equilibrated level of force. Addition of the drug vehicle had no appreciable effect on K þ -induced contraction (PSS for all compounds).
4.2.1.4. Statistical analysis. Data were analyzed using Student's ttest and are presented as mean ± S.E.M. Since the drugs were added in cumulative manner, the difference between the control and the experimental values at each concentration were tested for a P value < 0.05. The potency of drugs defined as EC 50 and IC 50 was evaluated from log concentration-response curves (Probit analysis using Litchfield and Wilcoxon) [35] in the appropriate pharmacological preparations. L-glutamine (Sigma-Aldrich, St. Louis, MO), 100 mg/mL penicillin and 100 mg/mL streptomycin (Sigma-Aldrich, St. Louis, MO) at 37 C in 5% CO 2 . For experiments, the cells were grown to 70% confluence and then were treated with test compounds in serum free media for the indicated times.
4.2.3.2. Cell viability assay. HepG2 cell viability was assessed using a conventional MTT reduction assay [37] . This method is based on the ability of viable cells to metabolize MTT, a water-soluble salt (yellow color), by cellular oxidoreductase into a water-insoluble blue formazan product. Therefore, the amount of formazan produced is proportional to the viable cells. Briefly, viable cells (10 4 / well) were plated into sterile 96-Well Cell Culture Cluster (Corning, NY 14831) and incubated with different concentrations (0.05e2 mM) of tested compounds for 2 h at 37 C in 5% CO 2 . At the end of incubation, the culture medium was replaced by a solution of MTT 0.5 mg/mL (Sigma-Aldrich, Milan, Italy) in PBS (Sigma-Aldrich, Milan, Italy). After 2 h incubation at 37 C in 5% CO 2 this solution was removed and 200 ml of DMSO was added to each well to dissolve the formazan product. Absorbance values at 570 nm were measured using a plate reader Victor V 3 (Perkin-Elmer) and DMSO medium was used as blank solution. Results are expressed as the percentage of MTT reduction respect to control cells. All experiments were carried out in sextuplicate and were repeated twice. 
